Sanofi India Ltd Share Price
As on 18 November 2025 at 23:54 IST
Sanofi India Q1 FY26 Results:
Profit for the period declined 33% to ₹69.5 crores in Q1 FY26, from ₹103.4 crores in Q1 FY25. Total income for the quarter decreased 11% year-on-year to ₹415 crores from ₹468 crores.
About Sanofi India Ltd
Sanofi India Ltd. is a prominent pharmaceutical company in India. It engages in the development, manufacturing, and marketing of a wide range of pharmaceutical products. The company was founded in May 1956. Sanofi India has been a significant player in the Indian pharmaceutical industry for many decades. The headquarters of the company is located in Mumbai, Maharashtra. Sanofi India's main products include Lantus (insulin glargine), Toujeo (insulin glargine), Amaryl (glimepiride), and Apidra (insulin glulisine). The company also offers medicines to treat various therapeutic areas. Sanofi India falls under the pharmaceutical and biotechnology sector. +
The Current prices are delayed, log in for live prices
LOGINOver 1 Month
-1.32%
Over 6 Months
-26.42%
Over 1 Year
-25.23%
Over 3 Years
-16.58%
Sanofi India Ltd Summary
Close ₹4,614.20
Open ₹4,613
High ₹4,650
Low ₹4,575.10
Volume 13,904
Net Turnover (in Cr) ₹6.42
52Wk High ₹6,717
52Wk Low ₹4,560
52Wk High / Low
4,560
6,717
Sanofi India Ltd Fundamentals
Key Financial Data
Market Cap (in Cr) ₹10,626.50
EPS (TTM) 160.35
Book Value (BV) 339.61
Div. Yield 2.53 %
P/E (TTM) 29.84
Price/Book Value 13.60
Delivery % 62.70 %
Face Value 10
Key Ratios
PE Ratio 34.05
PB Ratio 16.36
EV to Sales 6.87
PEG Ratio -1.08
ROA 46.05
ROE 47.15
Debt-Equity 0.02
Net Profit Margin 21.97
Operating Profit Margin 25.20
Sanofi India Ltd Financials
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2024 | FY 2023 |
|---|---|---|
| Total Revenue | 2,029.70 | 2,057.30 |
| Total Expenses | 1,560.60 | 1,546.60 |
| Profit Before Tax | 431.40 | 528.50 |
| Profit After Tax | 313.70 | 364.60 |
| Operating Profit After Depreciation | 470.60 | 512.40 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2024 | FY 2023 |
|---|---|---|
| Fixed Assets | 312.50 | 317.50 |
| Total Non Current Assets | 485 | 466.80 |
| Total Current Assets | 1,126.80 | 1,248 |
| Total Assets | 1,611.80 | 1,714.80 |
| Total Shareholder's Fund | 860.60 | 1,015.20 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2004 | FY 2003 |
|---|---|---|---|---|
| Net Cash From Operating Activities | 461.50 | 230.40 | 84.96 | 81.77 |
| Net Cash Used In Investing Activities | -179.80 | 37.50 | 2.23 | -21.60 |
| Net Cash Used In Financing Activities | -392.40 | -878.30 | -42.13 | -45.17 |
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Total Revenue | 2,029.70 | 2,057.30 | 2,841.60 | 3,031 | 2,991.70 |
| Total Expenses | 1,560.60 | 1,546.60 | 2,109.30 | 2,262.60 | 2,272.80 |
| Profit Before Tax | 431.40 | 528.50 | 864.30 | 1,257.60 | 677.20 |
| Profit After Tax | 313.70 | 364.60 | 620.60 | 944.40 | 477.60 |
| Operating Profit After Depreciation | 470.60 | 512.40 | 734 | 770.20 | 720.70 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Fixed Assets | 312.50 | 317.50 | 310.30 | 338 | 467.80 |
| Total Non Current Assets | 485 | 468.80 | 461.40 | 923.10 | 1,085.20 |
| Total Current Assets | 1,126.80 | 1,246.30 | 1,610.30 | 2,137.90 | 1,833.30 |
| Total Assets | 1,611.80 | 1,715.10 | 2,071.70 | 3,061 | 2,918.50 |
| Total Shareholder's Fund | 860.60 | 1,015.50 | 1,275.80 | 2,225.60 | 2,119 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 461.70 | 230.80 | 398.70 | 558.80 | 611.10 |
| Net Cash Used In Investing Activities | -178.40 | 35.50 | 650.90 | 630.80 | 276.40 |
| Net Cash Used In Financing Activities | -392.40 | -878.30 | -1,582.70 | -849 | -810 |
| Particulars (in ₹ Cr.) | 2024-12 | 2024-09 | 2024-06 | 2024-03 | 2023-12 |
|---|---|---|---|---|---|
| Total Revenue | 514.90 | 524 | 463.50 | 510.80 | 469.20 |
| Total Expenses | 396.60 | 404.30 | 347.80 | 373.70 | 369.60 |
| Profit Before Tax | 122.20 | 112.60 | 127.10 | 169.10 | 167.30 |
| Profit After Tax | 91.30 | 82.20 | 103.20 | 136.60 | 137.70 |
| Operating Profit after Depreciation | 124.20 | 122 | 155.50 | 205.20 | 177 |
| Particulars (in ₹ Cr.) | 2025-09 | 2025-06 | 2025-03 | 2024-12 | 2024-09 |
|---|---|---|---|---|---|
| Total Revenue | 475.40 | 406.30 | 535.90 | 514.90 | 524 |
| Total Expenses | 341.20 | 311.40 | 364 | 396.60 | 404.30 |
| Profit Before Tax | 102.30 | 94.10 | 165.30 | 122.20 | 112.60 |
| Profit After Tax | 76 | 69.50 | 119.50 | 91.30 | 82.20 |
| Operating Profit after Depreciation | 139.10 | 103.60 | 175.20 | 124.20 | 122 |
Sanofi India Ltd Technicals
Support and Resistance
S3 S2 S1 Pivot R1 R2 R3
S1 4,576.20
S2 4,538.20
S3 4,501.30
Pivot 4,613.10
R1 4,651.10
R2 4,688
R3 4,726
Moving Average
20 SMA 4,690.63
50 SMA 4,808.64
100 SMA 5,224.67
200 SMA 5,523.17
Sanofi India Ltd Corporate Actions
Sanofi India Ltd
₹75.0/Share
Announcement Date 07 Nov 2025
Record Date 07 Nov 2025
Div Yield 750%
Sanofi India Ltd Peer Comparison
| Company | Price | Market Cap (in Cr) |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹1,763.70 | ₹4,23,170.71 |
| Divis Laboratories Ltd | ₹6,523.25 | ₹1,73,171.79 |
| Torrent Pharmaceuticals Ltd | ₹3,816.75 | ₹1,29,170.36 |
| Cipla Ltd | ₹1,536.25 | ₹1,24,093.85 |
| Dr Reddys Laboratories Ltd | ₹1,244.50 | ₹1,03,868.61 |
Sanofi India Ltd Top Mutal Funds Invested
| Fund Name | AUM |
|---|---|
| Nippon India Pharma Fund | 1.32% |
| Aditya Birla SL Consumption Fund | 0.55% |
| SBI Midcap Fund | 0.52% |
| Aditya Birla SL Balanced Advantage Fund | 0.45% |
| Aditya Birla SL Large Cap Fund | 0.39% |
Sanofi India Ltd News
Board of Sanofi India recommends Interim Dividend
Of Rs.75 per share
29 Oct 2025, 01:42 pm
Board of Sanofi India approves change in directorate
At meeting held on 27 October 2025
27 Oct 2025, 06:04 pm
Sanofi India to table results
On 29 October 2025
23 Oct 2025, 05:35 pm
Sanofi India announces cessation of senior management personnel
14 Aug 2025, 09:31 am
Sanofi India to hold board meeting
On 31 July 2025
19 Jul 2025, 10:01 am
Sanofi India Ltd Stock Analysis
- Annual revenue for Sanofi India Ltd decreased by 1.34% to ₹2,029.70 crore in FY 2024 from ₹2,057.30 crore in FY 2023.
- Annual Net Profit for Sanofi India Ltd decreased by 13.96% to ₹313.70 crore in FY 2024 from ₹364.60 crore in FY 2023.
- Promoter Shareholding in Sanofi India Ltd remains unchanged by 0.00% in the most recent quarter, from 60.40% in June 2025 to 60.40% in September 2025.
- Sanofi India Ltd delivered a 1-year return of -25.23% compared to the Nifty 50, which provided a return of 10.91% as of the last trading session.
- Sanofi India Ltd share price moved down by 0.68% from its previous close of INR ₹4,614.20. The latest Sanofi India Ltd share price is INR ₹4,583.
- Sanofi India Ltd share price today has been at a low of 4,580 and a high of 4,623. Over the past 52 weeks, the Sanofi India Ltd share price has seen a low of 4,560 and a high of 6,717.
About Sanofi India Ltd
Sanofi India Ltd. is a leading pharmaceutical company in India. The company engages in the development, manufacturing, and marketing of a wide range of pharmaceutical products. It focuses on providing innovative treatments and preventive healthcare solutions. This solution includes vaccines to improve patient health and well-being. Sanofi India operates in various therapeutic areas, including diabetes, cardiology, thrombosis, central nervous system, and antihistamines.
Sanofi India falls under the pharmaceutical and biotechnology sector. Under the name Hoechst Fedco Pharma Private Limited, the company was established in May 1956. Over the years, it has undergone several name changes and is now a subsidiary of Sanofi, one of the world's leading healthcare companies. Sanofi India has been a significant player in the Indian pharmaceutical industry for many decades.
The headquarters of Sanofi India Ltd. is located in Mumbai, Maharashtra, India. The promoter shareholding in Sanofi India Ltd. stands at approximately 60.4%, demonstrating strong promoter commitment to the business. This promoter shareholding is held by Hoechst GMBH and Sanofi. They hold 60.37% and 0.02% stake of total shares.
Sanofi India's main products include a wide range of pharmaceutical drugs and vaccines. Some of the key products in its portfolio are Lantus (insulin glargine), Toujeo (insulin glargine), Clexane (enoxaparin sodium), Amaryl (glimepiride), and Apidra (insulin glulisine).
Sanofi India is one of the leading multinational pharmaceutical companies in India, with a strong market presence and a reputation for excellence. The company may not be the largest by market capitalization. However, its robust capabilities and extensive product portfolio have positioned it as a key player in the industry.
The registered office of Sanofi India Ltd. is located at CTS No.117-B, L&T Business Park, Saki Vihar Road, Powai, Mumbai - 400072, Maharashtra, India. Its registrar & transfer agent is Link Intime India Pvt. Ltd. The key managerial promoters of the company include:
Digital Transformation and Innovative Healthcare Solutions The cornerstone of Sanofi India's future strategy lies in comprehensive digital transformation. The company aims to create an integrated healthcare ecosystem that transcends traditional pharmaceutical boundaries. This will be done by embracing technological advancements. The change involves developing sophisticated digital platforms that combine telemedicine, AI-driven diagnostics, and personalized health monitoring. Sanofi India will not only streamline its internal processes but also provide more targeted, efficient healthcare solutions to patients.
Localized Research and Targeted Development Recognizing India's unique healthcare landscape, Sanofi India will intensify its focus on localized research and development. The company is establishing robust research centers and fostering collaborations with Indian academic institutions. With this establishment, it will develop cost-effective medications. These medications will be specifically tailored to address the prevalent health challenges in the region. This approach ensures that pharmaceutical innovations are not just globally competitive but also culturally and economically relevant to the Indian market.
Comprehensive Therapeutic Portfolio Expansion To maintain its market leadership, Sanofi India will strategically diversify its therapeutic portfolio. Moving beyond its current focus areas of diabetes, cardiology, and central nervous system treatments, the company will explore emerging domains such as oncology, immunology, and rare disease treatments.
Sustainability and Social Responsibility The organization aims to embed sustainability and social responsibility into its core business strategy. This comprehensive approach encompasses environmentally friendly manufacturing processes, sustainable packaging solutions, and targeted healthcare programs for underserved populations. Sanofi India demonstrates a strong commitment to holistic societal development. They do this by developing robust ESG frameworks and supporting healthcare infrastructure in rural and semi-urban regions.
Operational Excellence and Global Collaboration Sanofi India focuses on optimizing its manufacturing capabilities and supply chain. This will be accomplished through advanced automation, quality control technologies, and strategic partnerships. Simultaneously, the company will invest in talent development, creating comprehensive skill enhancement programs and establishing international knowledge exchange initiatives.
Emerging Market Strategy While maintaining a strong focus on the Indian market, Sanofi India strategically explores expansion opportunities in neighbouring regions. This involves developing region-specific product portfolios and deeply understanding diverse regional healthcare ecosystems. By adopting a nuanced, adaptive approach to market expansion, the company can effectively scale its operations while maintaining its core values of quality and patient care.
The future of Sanofi India Ltd. is not merely about pharmaceutical production but about creating a comprehensive healthcare ecosystem that prioritizes innovation, accessibility, and patient well-being. The company is poised to redefine healthcare delivery in India and beyond. They are going to do this by integrating advanced technologies and embedding social responsibility into its core strategy.
Sanofi India falls under the pharmaceutical and biotechnology sector. Under the name Hoechst Fedco Pharma Private Limited, the company was established in May 1956. Over the years, it has undergone several name changes and is now a subsidiary of Sanofi, one of the world's leading healthcare companies. Sanofi India has been a significant player in the Indian pharmaceutical industry for many decades.
The headquarters of Sanofi India Ltd. is located in Mumbai, Maharashtra, India. The promoter shareholding in Sanofi India Ltd. stands at approximately 60.4%, demonstrating strong promoter commitment to the business. This promoter shareholding is held by Hoechst GMBH and Sanofi. They hold 60.37% and 0.02% stake of total shares.
Sanofi India's main products include a wide range of pharmaceutical drugs and vaccines. Some of the key products in its portfolio are Lantus (insulin glargine), Toujeo (insulin glargine), Clexane (enoxaparin sodium), Amaryl (glimepiride), and Apidra (insulin glulisine).
Sanofi India is one of the leading multinational pharmaceutical companies in India, with a strong market presence and a reputation for excellence. The company may not be the largest by market capitalization. However, its robust capabilities and extensive product portfolio have positioned it as a key player in the industry.
The registered office of Sanofi India Ltd. is located at CTS No.117-B, L&T Business Park, Saki Vihar Road, Powai, Mumbai - 400072, Maharashtra, India. Its registrar & transfer agent is Link Intime India Pvt. Ltd. The key managerial promoters of the company include:
- Aditya Narayan
- Rodolfo Hrosz
- Rachid Ayari
- Renee Amonkar
- Vaibhav Karandikar
Future Strategy of the Company
In the rapidly transforming pharmaceutical landscape, Sanofi India Ltd. stands at a critical juncture of opportunity and challenge. It is a well-established pharmaceutical company with decades of rich history. Thus, the organization has reimagined its strategic approach to sustain growth, drive innovation, and address the evolving healthcare needs of India. The future success of Sanofi India is defined by its ability to seamlessly blend technological innovation, patient-centric solutions, and adaptive business strategies.Digital Transformation and Innovative Healthcare Solutions The cornerstone of Sanofi India's future strategy lies in comprehensive digital transformation. The company aims to create an integrated healthcare ecosystem that transcends traditional pharmaceutical boundaries. This will be done by embracing technological advancements. The change involves developing sophisticated digital platforms that combine telemedicine, AI-driven diagnostics, and personalized health monitoring. Sanofi India will not only streamline its internal processes but also provide more targeted, efficient healthcare solutions to patients.
Localized Research and Targeted Development Recognizing India's unique healthcare landscape, Sanofi India will intensify its focus on localized research and development. The company is establishing robust research centers and fostering collaborations with Indian academic institutions. With this establishment, it will develop cost-effective medications. These medications will be specifically tailored to address the prevalent health challenges in the region. This approach ensures that pharmaceutical innovations are not just globally competitive but also culturally and economically relevant to the Indian market.
Comprehensive Therapeutic Portfolio Expansion To maintain its market leadership, Sanofi India will strategically diversify its therapeutic portfolio. Moving beyond its current focus areas of diabetes, cardiology, and central nervous system treatments, the company will explore emerging domains such as oncology, immunology, and rare disease treatments.
Sustainability and Social Responsibility The organization aims to embed sustainability and social responsibility into its core business strategy. This comprehensive approach encompasses environmentally friendly manufacturing processes, sustainable packaging solutions, and targeted healthcare programs for underserved populations. Sanofi India demonstrates a strong commitment to holistic societal development. They do this by developing robust ESG frameworks and supporting healthcare infrastructure in rural and semi-urban regions.
Operational Excellence and Global Collaboration Sanofi India focuses on optimizing its manufacturing capabilities and supply chain. This will be accomplished through advanced automation, quality control technologies, and strategic partnerships. Simultaneously, the company will invest in talent development, creating comprehensive skill enhancement programs and establishing international knowledge exchange initiatives.
Emerging Market Strategy While maintaining a strong focus on the Indian market, Sanofi India strategically explores expansion opportunities in neighbouring regions. This involves developing region-specific product portfolios and deeply understanding diverse regional healthcare ecosystems. By adopting a nuanced, adaptive approach to market expansion, the company can effectively scale its operations while maintaining its core values of quality and patient care.
The future of Sanofi India Ltd. is not merely about pharmaceutical production but about creating a comprehensive healthcare ecosystem that prioritizes innovation, accessibility, and patient well-being. The company is poised to redefine healthcare delivery in India and beyond. They are going to do this by integrating advanced technologies and embedding social responsibility into its core strategy.
FAQ’s
What is the share price of Sanofi India Ltd today?
Sanofi India Ltd share price as on 18 Nov 2025 is ₹ 4583.0
What is the Market Cap of Sanofi India Ltd?
The market cap of Sanofi India Ltd stock is ₹10,626.50 Cr.
What is the PE Ratio of Sanofi India Ltd?
The Price to Earnings (P/E) Ratio of Sanofi India Ltd is 34.05
What is the PB Ratio of Sanofi India Ltd?
The Price to Book (P/B) Ratio of Sanofi India Ltd is 16.36
What is the 52 week high of Sanofi India Ltd Share Price?
The 52 week high of Sanofi India Ltd share price stands at ₹6,717
What is the 52 week low of Sanofi India Ltd Share Price?
The 52 week low of Sanofi India Ltd share price stands at ₹4,560
How can I buy shares of Sanofi India Ltd?
Simply open a demat account with Torus Digital and place an order to buy shares of Sanofi India Ltd.
Open FREE
3-in-1 Account
for all your banking, trading and demat needs
Trade in stocks,
derivatives and F&O
